San Diego-based Viking Therapeutics marked itself as a significant competitor within the weight loss drug market in February immediately after revealing promising information from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection and in March the